Genentech, Idec deal

GNE returned marketing rights to IDPH for IDEC-Y2B8, a radioimmunotherapy in Phase II trials to

Read the full 155 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE